Experimental model of multiple sclerosis: preclinical evaluation of the PI3K/Akt/mTOR pathway


The PI3K/AKT/mTOR pathway is an intracellular signalling pathway that regulates cell activation, proliferation, metabolism and apoptosis. Increasing body of data suggests that alterations in the PI3K/AKT/mTOR pathway may result in an enhanced susceptibility to autoimmunity.

Multiple sclerosis is one of the most common chronic inflammatory diseases of the central nervous system leading to demyelination and neurodegeneration.

Researchers have firstly evaluated in silico the involvement of the mTOR network on the generation and progression of multiple sclerosis and on oligodendrocyte function, making use of currently available whole-genome transcriptomic data.

Then, the data generated in silico were subjected to an ex-vivo evaluation. To this aim, the involvement of mTOR was validated on a well-known animal model of multiple sclerosis and in vitro on Th17 cells.

The data have indicated that there is a significant involvement of the mTOR network in the etiopathogenesis of multiple sclerosis and that Rapamycin treatment may represent a useful therapeutic approach in this clinical setting.

On the other hand, the data showed that a significant involvement of the mTOR network could be observed only in the early phases of oligodendrocyte maturation, but not in the maturation process of adult oligodendrocytes and in the process of remyelination following demyelinating injury.

Overall, the study has shown that targeting the PI3K/mTOR pathway, although it may not be a useful therapeutic approach to promote remyelination in patients with multiple sclerosis, it can be exploited to exert immunomodulation, preventing / delaying relapses, and to treat patients with multiple sclerosis in order to slow down the progression of disability. ( Xagena )

Mammana S et al, Oncotarget 2018; 9: 8263-8277

XagenaMedicine_2017



Indietro

Altri articoli

Venetoclax ( Venclexta ) in newly-diagnosed AML patients who are ineligible for intensive chemotherapy is supported by data from a...


UCSD ( University of California San Diego ) researchers have identified the molecular mechanism activated by the presence of tetrahydrocannabinol...


The European Commission has approved Venclyxto ( Venetoclax ) in combination with Gazyvaro ( Obinutuzumab ) for the treatment of...


Abemaciclib ( Verzenio ) in combination with standard adjuvant endocrine therapy has met the primary endpoint of invasive disease-free...


The U.S. Food and Drug Administration ( FDA ) has approved Venclexta ( Venetoclax ) in combination with Obinutuzumab (...


Data from the CLL14 trial, the first randomized clinical trial to examine stopping an oral-based, chemotherapy-free combination after 12 months...


Acute myeloid leukemia ( AML ) remains a highly resistant disease to conventional chemotherapy, with a median survival of only...


The European Commission has approved Tafinlar ( Dabrafenib ) in combination with Mekinist ( Trametinib ) for the adjuvant treatment...


In 2016, the National Institute for Health and Care Excellence ( NICE ) approved the use of Belimumab ( Benlysta...